enGene (NASDAQ:ENGN) Given "Buy" Rating at HC Wainwright

Key Points

• HC Wainwright reiterated a “Buy” rating on enGene and set a $4.00 price target, implying 112.2% upside from the prior close.
• Analyst sentiment remains mixed: four analysts rate the stock Buy, eight Hold, and two Sell, resulting in a consensus “Hold” rating and an $11.05 average target price.
• enGene shares rose 3.6% to $1.89, while the company reported a quarterly loss of $0.47 per share. Institutional investors own 64.16% of the stock.

enGene (NASDAQ:ENGN - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright's price objective suggests a potential upside of 112.20% from the stock's previous close.

A number of other analysts have also issued reports on the company. Weiss Ratings restated a "sell (e+)" rating on shares of enGene in a report on Wednesday, August 12th. Morgan Stanley lowered enGene from an "equal weight" rating to an "underweight" rating and set a $3.00 price target on the stock. in a research report on Thursday, June 18th. UBS Group dropped their price objective on shares of enGene from $9.00 to $2.00 and set a "neutral" rating on the stock in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of enGene from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, enGene currently has a consensus rating of "Hold" and a consensus target price of $11.05.

enGene Stock Up 3.6%

Shares of ENGN traded up $0.07 during midday trading on Tuesday, hitting $1.89. The company had a trading volume of 694,833 shares, compared to its average volume of 1,005,779. The company's 50 day moving average price is $1.82 and its 200 day moving average price is $4.11. The stock has a market cap of $126.28 million, a price-to-earnings ratio of -0.87 and a beta of -0.28. The company has a quick ratio of 12.57, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. enGene has a 52 week low of $1.40 and a 52 week high of $12.25.

enGene (NASDAQ:ENGN - Get Free Report) last released its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, hitting the consensus estimate of ($0.47). On average, equities research analysts predict that enGene will post -1.84 EPS for the current year.

Institutional Trading of enGene

Several large investors have recently made changes to their positions in the business. Cresset Asset Management LLC bought a new position in shares of enGene during the 2nd quarter valued at about $36,000. Raymond James Financial Inc. grew its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of enGene in the second quarter worth $38,000. Jump Financial LLC bought a new position in shares of enGene in the fourth quarter worth $121,000. Finally, Millennium Management LLC raised its stake in enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company's stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company's stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.